CompletedPhase 2NCT05163886
Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OrphAI Therapeutics
- Principal Investigator
- Suma Babu, M.D.Massachusetts General Hospital
- Intervention
- LAM-002A(drug)
- Enrollment
- 14 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (3)
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05163886 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)
- RECRUITINGPHASE3NCT07322003Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSPrilenia